ZincFive Expands Global Reach with Strategic EMEA Warehouse and Service Hub
22.5.2025 14:35:00 CEST | Business Wire | Press Release
ZincFive®, the world leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced a major milestone in its global growth strategy with the establishment of a new warehouse and service depot in Europe. The facility, operated in collaboration with Akkuteam Energietechnik GmbH, will support fast, efficient delivery of ZincFive batteries and spare parts across the EMEA region and beyond.
This certified customs warehouse enables seamless transit of batteries and components through Europe, streamlining exports to non-EU countries such as those in the Middle East. It also advances ZincFive’s sustainability goals by reducing shipping-related emissions and improving logistics efficiency.
The move comes in response to accelerating international demand for ZincFive’s nickel-zinc technology. With many European installations still relying on legacy lead-acid systems, there is a growing appetite for safer, more sustainable, and high-performance alternatives – making ZincFive’s technology uniquely suited to meet modern backup power needs.
“This is more than a logistical move – it’s a signal of our long-term commitment to the EMEA market,” said ZincFive CEO Tim Hysell. “Our values of innovation, sustainability, and reliability are mirrored in this new partnership. With a facility designed for efficient, environmentally responsible battery logistics, we’re not just expanding our footprint – we’re doing it the right way. We’re investing where demand is real and growing – this isn’t speculative; it’s a response to the strong pull we’re seeing from European and Middle Eastern markets.”
Akkuteam brings deep expertise in battery storage and handling and operates with a strong focus on quality and environmental stewardship. As a family-run company with a 25-year history of innovation in backup power solutions, Akkuteam’s commitment to service and future-ready infrastructure closely aligns with ZincFive’s mission to power a greener future through The Power of Good Chemistry®.
ZincFive is uniquely positioned for global growth as power demands rise across sectors – especially in data centers, including the fast-emerging AI segment. Its patented nickel-zinc chemistry – proven in the field for over a decade – delivers safe, sustainable, and high-performance energy storage that challenges the dominance of lead-acid and lithium-ion batteries. The ZincFive BC Series UPS Battery Cabinets – including the latest BC 2–500 and BC 2–300X models – offer an industry-leading footprint while delivering greater power to meet the escalating demands of modern infrastructure. Powered by the new Z5 13-90 ultra-high-rate battery, these solutions continue to raise the bar for compact design, reliability, and sustainability in mission-critical environments.
ZincFive has earned global recognition, including TIME’s 2025 World’s and America’s Top GreenTech Companies lists, the 2024 Edison Award™, CleanTech Breakthrough’s 2024 Overall Innovation of the Year, a finalist spot in the 2023 S&P Platts Global Energy Awards, and several other notable industry honors.
About ZincFive, Inc.
ZincFive is the world leader in innovation and delivery of nickel-zinc batteries and immediate power solutions. Supported by an impressive portfolio of international patents, ZincFive technology harnesses The Power of Good Chemistry® to propel the world forward. ZincFive technology leverages the safety and sustainability of nickel-zinc chemistry to provide unparalleled high power density and performance for mission critical applications. ZincFive is a privately held company based in Tualatin, Oregon. For more information, visit www.zincfive.com.
ZincFive and The Power of Good Chemistry are registered trademarks of ZincFive, Inc. and the ZincFive logo is a trademark of ZincFive, Inc.
Follow ZincFive: LinkedIn | YouTube
View source version on businesswire.com: https://www.businesswire.com/news/home/20250522279972/en/
Contacts
Media Contact:
Ilissa Miller
iMiller Public Relations for ZincFive
Tel: +1.914.315.6424
Email: zincfive@imillerpr.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom